ABBV Jan 2024 200.000 put
| Previous close | 48.67 |
| Open | 48.67 |
| Bid | 44.75 |
| Ask | 46.40 |
| Strike | 200.00 |
| Expiry date | 2024-01-19 |
| Day's range | 48.67 - 48.67 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
- Motley Fool
2 High-Yield Dividend Stocks You Won't Regret Buying Right Now
High-yield dividend stocks can be great for managing the ongoing reset in global equity markets. Which high-yield dividend stocks are worth buying right now? Read on to find out more about these above-average passive income opportunities.
- Zacks
AbbVie (ABBV) Gets FDA Rejection for Parkinson's Candidate
In the CRL, the FDA asks AbbVie (ABBV) for some extra information about the pump device used to administer the Parkinson's disease medicine, ABBV-951.
- PR Newswire
AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus
AbbVie (NYSE: ABBV) today announced topline results from a Phase 2 study of upadacitinib (RINVOQ®, 30 mg) given alone or as combination therapy (ABBV-599) with a Bruton's Tyrosine Kinase inhibitor (elsubrutinib, 60 mg), once daily in patients with moderately to severely active systemic lupus erythematosus (SLE).1 The SLEek study met the primary endpoint of SLE Responder Index (SRI-4) and steroid dose less than or equal to 10 mg prednisone equivalent once per day at week 24 in the upadacitinib 30
